Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Aquestive Therapeutics in a research report issued to clients and investors on Monday, March 10th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.17) for the quarter. HC Wainwright currently has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Aquestive Therapeutics' current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Aquestive Therapeutics' Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.61) EPS.
AQST has been the topic of several other reports. Cantor Fitzgerald initiated coverage on Aquestive Therapeutics in a report on Tuesday, December 17th. They set an "overweight" rating and a $17.00 target price on the stock. Lake Street Capital cut their target price on Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Friday, March 7th. Raymond James set a $7.00 price objective on Aquestive Therapeutics in a research note on Friday. Finally, Alliance Global Partners reissued a "buy" rating on shares of Aquestive Therapeutics in a research note on Friday. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Aquestive Therapeutics has a consensus rating of "Buy" and a consensus price target of $10.57.
Read Our Latest Research Report on Aquestive Therapeutics
Aquestive Therapeutics Trading Up 3.9 %
Shares of AQST opened at $2.64 on Wednesday. The company has a market capitalization of $261.02 million, a PE ratio of -5.87 and a beta of 2.76. Aquestive Therapeutics has a 12 month low of $2.24 and a 12 month high of $6.23. The stock's 50-day moving average price is $3.05 and its two-hundred day moving average price is $4.07.
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The business had revenue of $11.87 million during the quarter, compared to analysts' expectations of $13.11 million.
Institutional Trading of Aquestive Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AQST. Chartwell Investment Partners LLC bought a new stake in Aquestive Therapeutics in the 3rd quarter valued at about $535,000. GSA Capital Partners LLP increased its position in Aquestive Therapeutics by 525.5% in the 3rd quarter. GSA Capital Partners LLP now owns 137,151 shares of the company's stock valued at $683,000 after buying an additional 115,223 shares in the last quarter. Intech Investment Management LLC bought a new stake in Aquestive Therapeutics in the 3rd quarter valued at about $90,000. Charles Schwab Investment Management Inc. increased its position in Aquestive Therapeutics by 4.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 203,540 shares of the company's stock valued at $1,014,000 after buying an additional 9,268 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in Aquestive Therapeutics in the 3rd quarter valued at about $135,000. 32.45% of the stock is owned by institutional investors.
Aquestive Therapeutics Company Profile
(
Get Free Report)
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aquestive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.
While Aquestive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
